2 min read

Onesource Specialty Pharma Moat Analysis: Score & Risks

Moat Note · First-pass

Onesource Specialty Pharma Ltd.

A first-pass moat teardown of Onesource Specialty Pharma Ltd., built from single-pass filing evidence. Free note — provisional, and the full two-pass deep dive may revise it.

Moat & Margin16 Aug 2026 First-pass · ~3 min
5.49 / 10
NARROWProcess/Data-led

First-pass narrow read — primary edge in Efficient Scale. Provisional, single-pass evidence.

Provisional score · subject to modification based on new evidence

Onesource Specialty Pharma Ltd. scores 5.49 on MoatSCORE 6.0 — a narrow moat in Pharma. This is a first-pass note: the dimensional read and the filing receipts below come from a single GFIP evidence pass, not the full two-pass deep corpus behind our flagship deep dives. Provisional — published free while the deep version is queued.

The teardown

Seven dimensions of moat

Ordered by contribution. Each dimension carries a verified filing quote, graded [M] mechanism or [O] outcome.

D6Efficient Scale6.5
M · Mechanism Verified verbatim

“we have stopped onboarding new DDC customers simply because we do not have the capacities”

Onesource Specialty Pharma Ltd. · Earnings Call · p.4
D3Cost Advantage6
M · Mechanism Verified verbatim

“supported by operating leverage and optimised cost structures across our manufacturing network.”

Onesource Specialty Pharma Ltd. · FY2024-25 Annual Report · p.43
D2Switching Costs5.7
M · Mechanism Verified verbatim

“we have managed in most cases to extend the contractual obligations of our partners. And where we haven't, we obviously are now evoking the take-or-pay contractual obligations.”

Onesource Specialty Pharma Ltd. · Earnings Call · p.6
D4Price Discretion5.5
M · Mechanism Verified verbatim

“It will not be a price game. At least for the next couple of years, this will be an access game. This will be, for accessing capacity, companies will be willing to pay.”

Onesource Specialty Pharma Ltd. · Earnings Call · p.16
D5Intangible Assets4.8
No verified filing quote surfaced for this dimension in the first-pass evidence sweep.
D1Network Effects4.7
No verified filing quote surfaced for this dimension in the first-pass evidence sweep.
D7Counter-PositioningExcluded
Excluded for this archetype.
D8Ungoverned RiskUnscored · Layer 2.5

D8 rating: ADEQUATE. Not part of the moat score — it governs the cost of equity and the fade window. First-pass; not yet deep-reviewed.

The barrier gate

The barrier gate — first-pass

Replication — can a rival copy it?6.5
How hard it is for a rival to copy the edge (first-pass estimate).
Bypass — can a rival route around it?6.0
How easily a rival can route around the edge (first-pass estimate).

Effective barrier 6 — at or above 6, consistent with a narrow read. First-pass estimate.

What would change our mind
  1. Deep two-pass review. This draft rests on a single GFIP evidence pass; the full 10-year AR + concall corpus may move the read.

  2. The barrier gate. A firmer replication or bypass estimate is the most likely thing to shift the band.

  3. Adverse events. Any governance, regulatory or funding shock captured in D8 could re-rate the fade window.

First-pass note — provisional single-pass MoatSCORE 6.0 read, not the full deep dive. Educational research, not investment advice; no buy/sell recommendation, no price target. Moat & Margin is not a SEBI-registered Research Analyst or Investment Adviser.